Literature DB >> 33312677

Impact of proton radiotherapy on treatment timing in pediatric and adult patients with CNS tumors.

Michael C Jin1, Siyu Shi1, Adela Wu2, Navjot Sandhu1, Michael Xiang1, Scott G Soltys1, Susan Hiniker1,2, Gordon Li2, Erqi L Pollom3.   

Abstract

BACKGROUND: Despite putative benefits associated with proton radiotherapy in the setting of CNS tumors, numerous barriers limit treatment accessibility. Given these challenges, we explored the association of proton use with variations in treatment timing.
METHODS: Pediatric and adult patients with histologically confirmed CNS tumors were identified from the National Cancer Database (2004-2015). Univariable and multivariable regression models were constructed to assess factors impacting radiation timing. Multivariable Cox regression was used to evaluate the effect of treatment delay on survival.
RESULTS: A total of 76 157 patients received photon or proton radiotherapy. Compared to photons, time to proton administration was longer in multiple pediatric (embryonal, ependymal, nonependymal glial, and other) and adult (ependymal, nonependymal glial, meningeal, other) tumor histologies. On adjusted analysis, proton radiotherapy was associated with longer delays in radiotherapy administration in pediatric embryonal tumors (+3.00 weeks, P = .024) and in all adult tumors (embryonal [+1.36 weeks, P = .018], ependymal [+3.15 weeks, P < .001], germ cell [+2.65 weeks, P = .024], glial [+2.15 weeks, P < .001], meningeal [+5.05 weeks, P < .001], and other [+3.06 weeks, P < .001]). In patients with high-risk tumors receiving protons, delays in adjuvant radiotherapy were independently associated with poorer survival (continuous [weeks], adjusted hazard ratio = 1.09, 95% CI = 1.02-1.16).
CONCLUSIONS: Proton radiotherapy is associated with later radiation initiation in pediatric and adult patients with CNS tumors. In patients with high-risk CNS malignancies receiving protons, delayed adjuvant radiotherapy is associated with poorer survival. Further studies are needed to understand this discrepancy to maximize the potential of proton radiotherapy for CNS malignancies.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  central nervous system; particle therapy; proton therapy; radiation therapy; treatment planning

Year:  2020        PMID: 33312677      PMCID: PMC7716142          DOI: 10.1093/nop/npaa034

Source DB:  PubMed          Journal:  Neurooncol Pract        ISSN: 2054-2577


  33 in total

Review 1.  Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis.

Authors:  D De Ruysscher; B Lueza; C Le Péchoux; D H Johnson; M O'Brien; N Murray; S Spiro; X Wang; M Takada; B Lebeau; W Blackstock; D Skarlos; P Baas; H Choy; A Price; L Seymour; R Arriagada; J-P Pignon
Journal:  Ann Oncol       Date:  2016-07-19       Impact factor: 32.976

Review 2.  Clinical controversies: proton radiation therapy for brain and skull base tumors.

Authors:  Stephanie E Combs; Normand Laperriere; Michael Brada
Journal:  Semin Radiat Oncol       Date:  2013-04       Impact factor: 5.934

3.  Radiation-Induced Cerebral Microbleeds in Pediatric Patients With Brain Tumors Treated With Proton Radiation Therapy.

Authors:  Stephen F Kralik; Todd R Mereniuk; Laurent Grignon; Chie-Schin Shih; Chang Y Ho; Whitney Finke; Peter W Coleman; Gordon A Watson; Jeffrey C Buchsbaum
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-08-06       Impact factor: 7.038

4.  The Insurance Approval Process for Proton Radiation Therapy: A Significant Barrier to Patient Care.

Authors:  Matthew S Ning; Daniel R Gomez; Aashish K Shah; Charissa R Kim; Matthew B Palmer; Nikhil G Thaker; David R Grosshans; Zhongxing Liao; Bhavana V Chapman; Eric D Brooks; Chad Tang; David I Rosenthal; Adam S Garden; Steven J Frank; G Brandon Gunn
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-12-14       Impact factor: 7.038

5.  Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91.

Authors:  R D Kortmann; J Kühl; B Timmermann; U Mittler; C Urban; V Budach; E Richter; N Willich; M Flentje; F Berthold; I Slavc; J Wolff; C Meisner; O Wiestler; N Sörensen; M Warmuth-Metz; M Bamberg
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-01-15       Impact factor: 7.038

6.  Delay in radiotherapy shortens survival in patients with high grade glioma.

Authors:  Chris Irwin; Martin Hunn; Gordon Purdie; David Hamilton
Journal:  J Neurooncol       Date:  2007-06-20       Impact factor: 4.130

7.  Cranial irradiation increases risk of stroke in pediatric brain tumor survivors.

Authors:  Cynthia J Campen; Sarah M Kranick; Scott E Kasner; Sudha K Kessler; Robert A Zimmerman; Robert Lustig; Peter C Phillips; Phillip B Storm; Sabrina E Smith; Rebecca Ichord; Michael J Fisher
Journal:  Stroke       Date:  2012-09-11       Impact factor: 7.914

8.  Radiation Necrosis and White Matter Lesions in Pediatric Patients With Brain Tumors Treated With Pencil Beam Scanning Proton Therapy.

Authors:  Beat Bojaxhiu; Frank Ahlhelm; Marc Walser; Lorenzo Placidi; Ulrike Kliebsch; Lorentzos Mikroutsikos; Petra Morach; Alessandra Bolsi; Tony Lomax; Alessia Pica; Damien C Weber
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-12-01       Impact factor: 7.038

9.  Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial.

Authors:  Birgitta Lannering; Stefan Rutkowski; Francois Doz; Barry Pizer; Göran Gustafsson; Aurora Navajas; Maura Massimino; Roel Reddingius; Martin Benesch; Christian Carrie; Roger Taylor; Lorenza Gandola; Thomas Björk-Eriksson; Jordi Giralt; Foppe Oldenburger; Torsten Pietsch; Dominique Figarella-Branger; Keith Robson; Marco Forni; Steven C Clifford; Monica Warmuth-Metz; Katja von Hoff; Andreas Faldum; Véronique Mosseri; Rolf Kortmann
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544

10.  Impact of delays in initiating postoperative chemoradiation while determining the MGMT promoter-methylation statuses of patients with primary glioblastoma.

Authors:  Sebastian Adeberg; Tilman Bostel; Semi Harrabi; Denise Bernhardt; Thomas Welzel; Wolfgang Wick; Juergen Debus; Stephanie E Combs
Journal:  BMC Cancer       Date:  2015-07-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.